DNLI Q4 2020 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$317M+6681.1% YoY

Gross Profit

$317M100.0% margin

Operating Income

$244M77.0% margin

Net Income

$245M77.3% margin

EPS (Diluted)

$1.91

QoQ Revenue Growth

+3272.9%

Cash Flow

Operating Cash Flow

$514M

Free Cash Flow

$513M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$454M

Stockholders' Equity

$1.2B

Cash & Equivalents

$507M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$317M	$5M	+6681.1%
Gross Profit	$317M	$5M	+6681.1%
Operating Income	$244M	-$58M	+522.6%
Net Income	$245M	-$54M	+553.3%